Brokerages Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33

TScan Therapeutics, Inc. (NASDAQ:TCRX) has been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have covered the stock in the last year is $9.33.

TCRX has been the subject of a number of research reports. Needham & Company LLC decreased their target price on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Morgan Stanley reissued an “overweight” rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Friday, March 14th. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a report on Thursday, March 6th. Finally, Barclays decreased their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th.

TScan Therapeutics Trading Down 5.3 %

NASDAQ TCRX opened at $1.61 on Friday. TScan Therapeutics has a 12-month low of $1.44 and a 12-month high of $9.69. The company has a fifty day simple moving average of $2.18 and a two-hundred day simple moving average of $3.77. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock has a market cap of $91.11 million, a P/E ratio of -1.52 and a beta of 0.91.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $1.43 million. On average, analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current year.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in TScan Therapeutics during the fourth quarter valued at $32,000. Prudential Financial Inc. purchased a new stake in shares of TScan Therapeutics during the 4th quarter worth about $32,000. ProShare Advisors LLC acquired a new stake in shares of TScan Therapeutics during the 4th quarter valued at about $40,000. Wells Fargo & Company MN grew its position in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after acquiring an additional 5,694 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics in the 4th quarter valued at about $59,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.